Close

CTI BioPharma (CTIC) Announces Positive Pacritinib Preclinical Data in Myelofibrosis, AML Repopulating Cells

April 20, 2016 6:18 AM EDT Send to a Friend
CTI BioPharma Corp. (CTI) (Nasdaq: CTIC) announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login